Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05335512
Other study ID # 3505
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date September 1, 2028

Study information

Verified date June 2022
Source Tata Memorial Centre
Contact Mahendra Pal, DNB
Phone 9757091924
Email mahen1197@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective cohort and Prospective observational study which aims To define the healing time-frame of the resected area of the bladder after TURBT. and also to validate a grading system of healing of the bladder mucosa after TURBT. To assess the factors influencing bladder healing is also one of the secondary objectives.


Description:

This study will be offered to patients who are coming to Tata Memorial Hospital (TMH) for management of Non Muscular Invasive bladder cancer. 10 patients who undergo Transurethral resection of Bladder tumour will be enrolled. Any patient who undergoes TURBT in TMH, found to have NMIBC and gives consent is eligible for the study. Patient who has visible tumor on first or any subsequent cystoscopy are not eligible. 100 patients (40 private category & 60 general category patients) will be recruited, and they will be planned for cystoscopy in the minor operation theater under antibiotic cover and local anaesthesia at 2nd week, 3rd week, 4th week after the date of TURBT. Apprehensive or uncooperative patient will undergo procedure under general anaesthesia. Patients having non healed bladder mucosa at 4 weeks will be reassessed after a further 1week by additional cystoscopy.Each time of cystoscopy a photo of the healing resected area will be captured and will be used to compare with the next photo in the same patient to see the progress of healing. These photos will be assess by two experienced uro-oncologist to characterize the healing status of bladder.This comparison will be used to establish a grading system of bladder healing. The remaining cystoscopies will be performed as per guidelines. Urine routine microscopy and culture/sensitivity will be done before every cystoscopy to rule out urinary tract infection and to quantify the numbers of white blood cells the WBC count will be correlated with the degree of inflammation and phases of healing as additional marker. Patients who have healed or near healed resection area on any cystoscopy as per study protocol will be given IVB in the same setting if the patient is stratified as high risk NMIBC. Patients who will be stratified as low-risk NMIBC and has healed resection area will not have further cystoscopy as per study protocol but will undergo cystoscopy later as per guideline's schedule. Any patient having unhealed resection on cystoscopy will be planned for next cystoscopy as per protocol and IVB will not be given at this cystoscopy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date September 1, 2028
Est. primary completion date September 1, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Patients undergoing complete TURBT for evaluation of a newly diagnosed bladder lesion in TMH and found to have NMIBC (either low risk or high risk) Patient gives consent will be included (after explaining about the study). Exclusion Criteria: 1. Patient who has visible tumor on first or any subsequent cystoscopy. 2. On histopathology found to have muscle invasive bladder cancer. 3. Patient having urinary tract infection before cystoscopy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tata Memorial Centre

Outcome

Type Measure Description Time frame Safety issue
Primary Time Frame after TURBT To define the healing time-frame of the resected area of the bladder after TURBT. 1 year
Secondary Validate Grading System The score is from grade 1 to grade 4, the title for grading 'Grading of healing with time', minimum value 1 is while maximum value 4 is and higher scores means a worst outcome 1 year
Secondary Assessment Factors To assess the factors influencing bladder healing. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04617743 - The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression
Completed NCT04647981 - Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.
Not yet recruiting NCT05037279 - Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Phase 3
Recruiting NCT05768347 - Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC Phase 1